The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Molecular targeted therapy of glioblastoma
Open accessAbstract
Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH)-wildtype tumors. Incidence increases with age, males are more often affected. Beyond rare instances of genetic predisposition and irradiation exposure, there are no known glioblastoma risk factors. Surgery as safely feasible followed by involved-field radiotherapy plus concomitant and maintenance temozolomide chemotherapy define the standard of care since 2005. Except for prolonged progression-free, but not overall survival afforded by the vascular endothelial growth factor antibody, bevacizumab, no pharmacological intervention has been demonstrated to alter the course of disease. Specifically, targeting cellular pathways frequently altered in glioblastoma, such as the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), the p53 and the retinoblastoma (RB) pathways, or epidermal growth factor receptor (EGFR) gene amplification or mutation, have failed to improve outcome, likely because of redundant compensatory mechanisms, insufficient target coverage related in part to the blood brain barrier, or poor tolerability and safety. Yet, uncommon glioblastoma subsets may exhibit specific vulnerabilities amenable to targeted interventions, including, but not limited to: high tumor mutational burden, BRAF mutation, neurotrophic tryrosine receptor kinase (NTRK) or fibroblast growth factor receptor (FGFR) gene fusions, and MET gene amplification or fusions. There is increasing interest in targeting not only the tumor cells, but also the microenvironment, including blood vessels, the monocyte/macrophage/microglia compartment, or T cells. Improved clinical trial designs using pharmacodynamic endpoints in enriched patient populations will be required to develop better treatments for glioblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationThe 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
Self-citationMGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
DNA methylation-based classification of central nervous system tumours
Capper, D., Jones, D. T. W., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chavez, L., Reuss, D. E., et al. (2018) · Nature · doi:10.1038/nature26000 · Cited by 3,033
Self-citationA Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
Self-citationBevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Self-citationSturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828
Self-citationO’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,803
TERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma
Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904059 · Cited by 1,389
Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,134
Self-citationWeller, M., Wick, W., Aldape, K., Brada, M., Berger, M., Pfister, S. M., Nishikawa, R., Rosenthal, M., Wen, P. Y., Stupp, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.17 · Cited by 1,124
Self-citationWeller, M., van den Bent, M., Tonn, J. C., Stupp, R., Preusser, M., Cohen-Jonathan-Moyal, E., Henriksson, R., Rhun, E. L., Balana, C., Chinot, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,088
Self-citationStupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052
Self-citationLomustine and Bevacizumab in Progressive Glioblastoma
Wick, W., Gorlia, T., Bendszus, M., Taphoorn, M., Sahm, F., Harting, I., Brandes, A. A., Taal, W., Domont, J., Idbaih, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707358 · Cited by 970
Self-citationBrat, D. J., Aldape, K., Colman, H., Holland, E. C., Louis, D. N., Jenkins, R. B., Kleinschmidt-DeMasters, B. K., Perry, A., Reifenberger, G., Stupp, R., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1913-0 · Cited by 896
Self-citationStupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862
Bouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Singh, D., Chan, J. M., Zoppoli, P., Niola, F., Sullivan, R., Castano, A., Liu, E. M., Reichel, J., Porrati, P., Pellegatta, S., et al. (2012) · Science · doi:10.1126/science.1220834 · Cited by 789
Taal, W., Oosterkamp, H. M., Walenkamp, A. M. E., Dubbink, H. J., Beerepoot, L. V., Hanse, M. C. J., Buter, J., Honkoop, A. H., Boerman, D., de Vos, F. Y. F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70314-6 · Cited by 759
Self-citationStupp, R., Taillibert, S., Kanner, A. A., Read, W. L., Steinberg, D. M., Lhermitte, B., Toms, S. A., Idbaïh, A., Ahluwalia, M. S., Fink, K., et al. (2017) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · doi:10.5167/uzh-143757 · Cited by 630
Self-citationBatchelor, T. T., Mulholland, P., Neyns, B., Nabors, L. B., Campone, M., Wick, A., Mason, W., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 614
Self-citationPD-L1 expression and prognostic impact in glioblastoma
Nduom, E. K., Wei, J., Yaghi, N. K., Huang, N., Kong, L.-Y., Gabrusiewicz, K., Ling, X., Zhou, S., Ivan, C., Chen, J. Q., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov172 · Cited by 596
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Berghoff, A. S., Kiesel, B., Widhalm, G., Rajky, O., Ricken, G., Wöhrer, A., Dieckmann, K., Filipits, M., Brandstetter, A., Weller, M., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou307 · Cited by 585
Self-citationvan den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clement, P. M., Frenay, M., Campone, M., Baurain, J.-F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 575
Self-citationWick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L. M., Mason, W., Weller, M., Hong, S., Musib, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 525
Self-citationBatchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520
Self-citationReardon, D. A., Fink, K. L., Mikkelsen, T., Cloughesy, T. F., O'Neill, A., Plotkin, S., Glantz, M., Ravin, P., Raizer, J. J., Rich, K. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7510 · Cited by 481
Self-citationPlate, K. H., Breier, G., Weich, H. A., Mennel, H. D., & Risau, W. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590415 · Cited by 463
Stupp, R., Hegi, M. E., Neyns, B., Goldbrunner, R., Schlegel, U., Clement, P. M. J., Grabenbauer, G. G., Ochsenbein, A. F., Simon, M., Dietrich, P.-Y., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6650 · Cited by 454
Self-citationBogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq142 · Cited by 433
Lombardi, G., De Salvo, G. L., Brandes, A. A., Eoli, M., Rudà, R., Faedi, M., Lolli, I., Pace, A., Daniele, B., Pasqualetti, F., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30675-2 · Cited by 397
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Chang, S. M., Wen, P., Cloughesy, T., Greenberg, H., Schiff, D., Conrad, C., Fink, K., Robins, H. I., De Angelis, L., Raizer, J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1444-0 · Cited by 395
Self-citationBRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
Kaley, T., Touat, M., Subbiah, V., Hollebecque, A., Rodon, J., Lockhart, A. C., Keedy, V., Bielle, F., Hofheinz, R.-D., Joly, F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9990 · Cited by 350
Reardon, D. A., Omuro, A., Brandes, A. A., Rieger, J., Wick, A., Sepulveda, J., Phuphanich, S., de Souza, P., Ahluwalia, M. S., Lim, M., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox036.071 · Cited by 325
Self-citationWeller, M., Tabatabai, G., Kästner, B., Felsberg, J., Steinbach, J. P., Wick, A., Schnell, O., Hau, P., Herrlinger, U., Sabel, M. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2737 · Cited by 319
Self-citationDetection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Di Stefano, A. L., Fucci, A., Frattini, V., Labussiere, M., Mokhtari, K., Zoppoli, P., Marie, Y., Bruno, A., Boisselier, B., Giry, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2199 · Cited by 293
Sandmann, T., Bourgon, R., Garcia, J., Li, C., Cloughesy, T., Chinot, O. L., Wick, W., Nishikawa, R., Mason, W., Henriksson, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5005 · Cited by 293
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
Weller, M., Gorlia, T., Cairncross, J. G., van den Bent, M. J., Mason, W., Belanger, K., Brandes, A. A., Bogdahn, U., Macdonald, D. R., Forsyth, P., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822f02e1 · Cited by 290
Self-citationBrandes, A. A., Carpentier, A. F., Kesari, S., Sepulveda-Sanchez, J. M., Wheeler, H. R., Chinot, O., Cher, L., Steinbach, J. P., Capper, D., Specenier, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now009 · Cited by 273
c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype
Li, Y., Li, A., Glas, M., Lal, B., Ying, M., Sang, Y., Xia, S., Trageser, D., Guerrero-Cázares, H., Eberhart, C. G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016912108 · Cited by 266
Epithelioid GBMs Show a High Percentage of BRAF V600E Mutation
Kleinschmidt-DeMasters, B. K., Aisner, D. L., Birks, D. K., & Foreman, N. K. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31827f9c5e · Cited by 260
Lassman, A. B., Rossi, M. R., Razier, J. R., Abrey, L. E., Lieberman, F. S., Grefe, C. N., Lamborn, K., Pao, W., Shih, A. H., Kuhn, J. G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0421 · Cited by 252
Self-citationNabors, L. B., Fink, K. L., Mikkelsen, T., Grujicic, D., Tarnawski, R., Nam, D. H., Mazurkiewicz, M., Salacz, M., Ashby, L., Zagonel, V., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou356 · Cited by 242
Self-citationRecurrent MET fusion genes represent a drug target in pediatric glioblastoma
International Cancer Genome Consortium PedBrain Tumor Project (2016) · Nature Medicine · doi:10.1038/nm.4204 · Cited by 233
de Groot, J. F., Lamborn, K. R., Chang, S. M., Gilbert, M. R., Cloughesy, T. F., Aldape, K., Yao, J., Jackson, E. F., Lieberman, F., Robins, H. I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1636 · Cited by 228
Self-citationAdaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE
Alexander, B. M., Ba, S., Berger, M. S., Berry, D. A., Cavenee, W. K., Chang, S. M., Cloughesy, T. F., Jiang, T., Khasraw, M., Li, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0764 · Cited by 223
Self-citationFriday, B. B., Anderson, S. K., Buckner, J., Yu, C., Giannini, C., Geoffroy, F., Schwerkoske, J., Mazurczak, M., Gross, H., Pajon, E., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nor198 · Cited by 213
Happold, C., Gorlia, T., Chinot, O., Gilbert, M. R., Nabors, L. B., Wick, W., Pugh, S. L., Hegi, M., Cloughesy, T., Roth, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.6563 · Cited by 210
Self-citationKrauze, A. V., Myrehaug, S. D., Chang, M. G., Holdford, D. J., Smith, S., Shih, J., Tofilon, P. J., Fine, H. A., & Camphausen, K. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.04.038 · Cited by 204
Herrlinger, U., Schäfer, N., Steinbach, J. P., Weyerbrock, A., Hau, P., Goldbrunner, R., Friedrich, F., Rohde, V., Ringel, F., Schlegel, U., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4691 · Cited by 201
Hegi, M. E., Diserens, A.-C., Bady, P., Kamoshima, Y., Kouwenhoven, M. C. M., Delorenzi, M., Lambiv, W. L., Hamou, M.-F., Matter, M. S., Koch, A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0048 · Cited by 194
Felsberg, J., Hentschel, B., Kaulich, K., Gramatzki, D., Zacher, A., Malzkorn, B., Kamp, M., Sabel, M., Simon, M., Westphal, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0890 · Cited by 189
Self-citationvan den Bent, M. J., Gao, Y., Kerkhof, M., Kros, J. M., Gorlia, T., van Zwieten, K., Prince, J., van Duinen, S., Sillevis Smitt, P. A., Taphoorn, M., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov013 · Cited by 180
Self-citationWen, P. Y., Schiff, D., Cloughesy, T. F., Raizer, J. J., Laterra, J., Smitt, M., Wolf, M., Oliner, K. S., Anderson, A., Zhu, M., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq198 · Cited by 173
Self-citationGrossman, S. A., Ye, X., Chamberlain, M., Mikkelsen, T., Batchelor, T., Desideri, S., Piantadosi, S., Fisher, J., & Fine, H. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6895 · Cited by 172
Ma, D. J., Galanis, E., Anderson, S. K., Schiff, D., Kaufmann, T. J., Peller, P. J., Giannini, C., Brown, P. D., Uhm, J. H., McGraw, S., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou328 · Cited by 171
Wen, P. Y., Touat, M., Alexander, B. M., Mellinghoff, I. K., Ramkissoon, S., McCluskey, C. S., Pelton, K., Haidar, S., Basu, S. S., Gaffey, S. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01207 · Cited by 169
Self-citationWick, W., Gorlia, T., Bady, P., Platten, M., van den Bent, M. J., Taphoorn, M. J. B., Steuve, J., Brandes, A. A., Hamou, M.-F., Wick, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3153 · Cited by 159
Self-citationBobustuc, G. C., Baker, C. H., Limaye, A., Jenkins, W. D., Pearl, G. S., Avgeropoulos, N. G., & Konduri, S. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq044 · Cited by 156
Hegi, M. E., Genbrugge, E., Gorlia, T., Stupp, R., Gilbert, M. R., Chinot, O. L., Nabors, B., Jones, G., Criekinge, W. V., Straub, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3181 · Cited by 155
Self-citationCloughesy, T. F., Finocchiaro, G., Belda-Iniesta, C., Recht, L. D., Brandes, A. A., Pineda, E., Mikkelsen, T., Chinot, O. L., Balañá, C., Macdonald, D. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.7685 · Cited by 150
Self-citationWick, W., Dettmer, S., Berberich, A., Keßler, T., Karapanagiotou‐Schenkel, I., Wick, A., Winkler, F., Pfaff, E., Brors, B., Debus, J., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy161 · Cited by 148
Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Sulman, E. P., & Mehta, M. P. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1403303 · Cited by 142
Korshunov, A., Chávez, L., Sharma, T., Ryzhova, M. V., Schrimpf, D., Stichel, D., Capper, D., Sturm, D., Kool, M., Habel, A., et al. (2017) · Brain Pathology · doi:10.1111/bpa.12566 · Cited by 136
Wick, W., Fricke, H., Junge, K., Kobyakov, G., Martens, T., Heese, O., Wiestler, B., Schliesser, M. G., von Deimling, A., Pichler, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0951-t · Cited by 135
Nabors, B., Mikkelsen, T., Hegi, M. E., Ye, X., Batchelor, T. T., Lesser, G. J., Peereboom, D. M., Rosenfeld, M. R., Olsen, J., Brem, S., et al. (2012) · Cancer · doi:10.1002/cncr.27585 · Cited by 132
Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma
Taylor, J. W., Parikh, M., Phillips, J. J., James, C. D., Molinaro, A. M., Butowski, N. A., Clarke, J. L., Oberheim-Bush, N. A., Chang, S. M., Berger, M. S., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2977-3 · Cited by 129
Wen, P. Y., Drappatz, J., de Groot, J., Prados, M. D., Reardon, D. A., Schiff, D., Chamberlain, M. C., Mikkelsen, T., Desjardins, A., Holland, J. S., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox154 · Cited by 125
Self-citationIWAMOTO, F. M., Kreisl, T. N., Kim, L., Duic, J. P., Butman, J. A., Albert, P. S., & Fine, H. A. (2010) · Cancer · doi:10.1002/cncr.24957 · Cited by 123
Integrin control of the transforming growth factor-β pathway in glioblastoma
Roth, P., Silginer, M., Goodman, S. L., Hasenbach, K., Thies, S., Maurer, G., Schraml, P., Tabatabai, G., Moch, H., Tritschler, I., et al. (2013) · Brain · doi:10.1093/brain/aws351 · Cited by 120
Self-citationLee, E. Q., Kaley, T. J., Duda, D. G., Schiff, D., Lassman, A. B., Wong, E. T., Mikkelsen, T., Purow, B. W., Muzikansky, A., Ancukiewicz, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3220 · Cited by 119
Self-citationChi, A. S., Batchelor, T. T., Kwak, E. L., Clark, J. W., Wang, D. L., Wilner, K. D., Louis, D. N., & Iafrate, A. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4586 · Cited by 110
Transforming growth factor-β pathway activity in glioblastoma
Frei, K., Gramatzki, D., Tritschler, I., Schroeder, J. J., Espinoza, L., Rushing, E. J., & Weller, M. (2015) · Oncotarget · doi:10.18632/oncotarget.3467 · Cited by 104
Self-citationTargetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas
Ferguson, S. D., Zhou, S., Huse, J. T., de Groot, J., Xiu, J., Subramaniam, D. S., Mehta, S. V., Gatalica, Z., Swensen, J. J., Sanai, N., et al. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly022 · Cited by 103
Wirsching, H., Tabatabai, G., Roelcke, U., Hottinger, A. F., Jörger, F., Schmid, A., Plaßwilm, L., Schrimpf, D., Mancao, C., Capper, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy120 · Cited by 91
Self-citationBrandes, A. A., Finocchiaro, G., Zagonel, V., Reni, M., Caserta, C., Fabi, A., Clavarezza, M., Maiello, E., Eoli, M., Lombardi, G., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now035 · Cited by 86
Szabó, E., Schneider, H., Seystahl, K., Rushing, E. J., Herting, F., Weidner, K. M., & Weller, M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now043 · Cited by 83
Self-citationCloughesy, T. F., Drappatz, J., de Groot, J., Prados, M. D., Reardon, D. A., Schiff, D., Chamberlain, M. C., Mikkelsen, T., Desjardins, A., Ping, J., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox151 · Cited by 71
Self-citationGedeon, P. C., Schaller, T. H., Chitneni, S. K., Choi, B. D., Kuan, C., Suryadevara, C. M., Snyder, D. J., Schmittling, R. J., Szafranski, S. E., Cui, X., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0126 · Cited by 62
Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis
Seliger, C., Genbrugge, E., Gorlia, T., Chinot, O. L., Stupp, R., Nabors, B., Weller, M., Hau, P., & for the EORTC Brain Tumor Group (2019) · International Journal of Cancer · doi:10.1002/ijc.32337 · Cited by 62
Self-citationTakahashi, M., Miki, S., Fujimoto, K., Fukuoka, K., Matsushita, Y., Maida, Y., Yasukawa, M., Hayashi, M., Shinkyo, R., Kikuchi, K., et al. (2019) · Cancer Science · doi:10.1111/cas.14067 · Cited by 62
Wick, W., Steinbach, J. P., Platten, M., Hartmann, C. J., Wenz, F. K., von Deimling, A., Shei, P., MOREAU, V., Stoffregen, C., & Combs, S. E. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not100 · Cited by 61
Kong, X., Nguyen, N. T., Choi, Y. J., Zhang, G., Nguyen, H. N., Filka, E., Green, S., Yong, W. H., Liau, L. M., Green, R. M., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.01.001 · Cited by 60
C-MET overexpression and amplification in gliomas.
Kwak, Y., Kim, S. I., Park, C., Paek, S. H., Lee, S., & Park, S. (2015) · PubMed Central · Cited by 54
Reardon, D. A., Lassman, A. B., Schiff, D., Yunus, S. A., Gerstner, E. R., Cloughesy, T. F., Lee, E. Q., Gaffey, S. C., Barrs, J., Bruno, J., et al. (2018) · Cancer · doi:10.1002/cncr.31172 · Cited by 50
Self-citationEuropean perspective for effective cancer drug development
Lacombe, D., Tejpar, S., Salgado, R., Cardoso, F., Golfinopoulos, V., Aust, D. E., Folprecht, G., Roth, A. D., & Stupp, R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.98 · Cited by 42
Cited by
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citationMechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Singh, N., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 398
Verdugo, E., Puerto, I., & Medina, M. Á. (2022) · Cancer Communications · doi:10.1002/cac2.12361 · Cited by 253
VRK1 is a synthetic-lethal target in VRK2-deficient glioblastoma
Shields, J. A., Meier, S. R., Bandi, M., Mulkearns-Hubert, E. E., Hajdari, N., Ferdinez, M. D., Engel, J. L., Silver, D. J., Shen, B., Zhang, W., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4443 · Cited by 60
Unraveling the impact of miR-21 on apoptosis regulation in glioblastoma
Shaikh, M. A. J., Altamimi, A. S. A., Afzal, M., Gupta, G., Singla, N., Gilhotra, R., almalki, W. H., Kazmi, I., Alzarea, S. I., Prasher, P., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155121 · Cited by 37
Metadata
- Authors
- Le Rhun, E., Preusser, M., Roth, P., Reardon, D. A., van den Bent, M., Wen, P., Reifenberger, G., & Weller, M.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 80
- Pages
- 101896
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2973085389
- Cited by
- 688
- References
- 93
- FWCI
- 36.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.